<p>中國廣州，2025 年 12 月 22 日（GLOBE NEWSWIRE）——燃石醫學（NASDAQ: BNR，以下簡稱 “ <strong>公司</strong>” 或 “ <strong>燃石</strong>”）是一家專注於在精準腫瘤學領域應用下一代測序（NGS）技術的公司，今天宣佈在公司於今日召開的 2025 年年度股東大會上，所有提議的股東決議均已通過。具體而言，股東通過了以下決議：</p>
<ol>
<li>作為普通決議，批准安永華明會計師事務所擔任公司截至 2025 年 12 月 31 日的審計師，並授權公司董事決定審計師的報酬；</li>
</ol>
<ol>
<li>作為普通決議，重新選舉鄧峯和許麗岑為公司董事；</li>
</ol>
<ol>
<li>作為普通決議，授權公司每位董事採取任何必要行動，以實施上述決議，具體由該董事自行決定。</li>
</ol>
<p><strong>關於燃石</strong></p>
<p>燃石醫學（NASDAQ: BNR）的使命是通過科學守護生命，專注於在精準腫瘤學領域應用下一代測序（NGS）技術。其業務包括：i) 針對晚期癌症患者的基於 NGS 的治療選擇檢測，以及 ii) 癌症早期檢測，已從概念驗證研發階段進入臨牀驗證階段。</p>
<p>有關燃石的更多信息，請訪問：ir.brbiotech.com。</p>
<p>聯繫方式：IR@brbiotech.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qUXdNQ00zTXpNME1qWXhJekl4T1RVeU5Uaz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qUXdNQ00zTXpNME1qWXhJekl4T1RVeU5Uaz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWU0NmYwYTctMGU2My00MDgzLTk4NjItNDllNTQ3ZTc1M2Q0LTEyMDY4MTItMjAyNS0xMi0yMy1lbg==/tiny/Burning-Rock-Biotech-Limited.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWU0NmYwYTctMGU2My00MDgzLTk4NjItNDllNTQ3ZTc1M2Q0LTEyMDY4MTItMjAyNS0xMi0yMy1lbg==/tiny/Burning-Rock-Biotech-Limited.png"/></p>

燃石醫學

<p>燃石醫學有限公司宣佈，2025 年年度股東大會上的所有股東決議均已通過。決議包括確認安永華明會計師事務所為審計師，重新選舉鄧峯和許麗岑為董事，以及授權董事實施這些決議。燃石醫學專注於精準腫瘤學中的下一代測序（NGS）技術</p>

<p>GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “ <strong>Company</strong>” or “ <strong>Burning Rock</strong>”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2025 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions:</p>
<div class="lb-trans"><p>中國廣州，2025 年 12 月 22 日（GLOBE NEWSWIRE）——燃石醫學（NASDAQ: BNR，以下簡稱 “ <strong>公司</strong>” 或 “ <strong>燃石</strong>”）是一家專注於在精準腫瘤學領域應用下一代測序（NGS）技術的公司，今天宣佈在公司於今日召開的 2025 年年度股東大會上，所有提議的股東決議均已通過。具體而言，股東通過了以下決議：</p>
</div><ol>
<li>as an ordinary resolution, THAT the appointment of Ernst &amp; Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2025 be ratified and that the directors of the Company be authorized to determine the remuneration of the auditor;</li>
</ol>
<div class="lb-trans"><ol>
<li>作為普通決議，批准安永華明會計師事務所擔任公司截至 2025 年 12 月 31 日的審計師，並授權公司董事決定審計師的報酬；</li>
</ol>
</div><ol>
<li>as an ordinary resolution, THAT Feng Deng and Licen Lisa Xu be re-elected as directors of the Company; and</li>
</ol>
<div class="lb-trans"><ol>
<li>作為普通決議，重新選舉鄧峯和許麗岑為公司董事；</li>
</ol>
</div><ol>
<li>as an ordinary resolution, THAT each of the directors of the Company be authorized to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.</li>
</ol>
<div class="lb-trans"><ol>
<li>作為普通決議，授權公司每位董事採取任何必要行動，以實施上述決議，具體由該董事自行決定。</li>
</ol>
</div><p><strong>About Burning Rock</strong></p>
<div class="lb-trans"><p><strong>關於燃石</strong></p>
</div><p>Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&amp;D into the clinical validation stage.</p>
<div class="lb-trans"><p>燃石醫學（NASDAQ: BNR）的使命是通過科學守護生命，專注於在精準腫瘤學領域應用下一代測序（NGS）技術。其業務包括：i) 針對晚期癌症患者的基於 NGS 的治療選擇檢測，以及 ii) 癌症早期檢測，已從概念驗證研發階段進入臨牀驗證階段。</p>
</div><p>For more information about Burning Rock, please visit: ir.brbiotech.com.</p>
<div class="lb-trans"><p>有關燃石的更多信息，請訪問：ir.brbiotech.com。</p>
</div><p>Contact: IR@brbiotech.com</p>
<div class="lb-trans"><p>聯繫方式：IR@brbiotech.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qUXdNQ00zTXpNME1qWXhJekl4T1RVeU5Uaz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjQwMCM3MzM0MjYxIzIxOTUyNTk="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWU0NmYwYTctMGU2My00MDgzLTk4NjItNDllNTQ3ZTc1M2Q0LTEyMDY4MTItMjAyNS0xMi0yMy1lbg==/tiny/Burning-Rock-Biotech-Limited.png" alt="" original-src="https://ml.globenewswire.com/media/ZWU0NmYwYTctMGU2My00MDgzLTk4NjItNDllNTQ3ZTc1M2Q0LTEyMDY4MTItMjAyNS0xMi0yMy1lbg==/tiny/Burning-Rock-Biotech-Limited.png"/></p>

燃石醫學公佈 2025 年度股東大會結果 | BNR 股票新聞